Highest-materiality recent filing
Ascend Wellness Q1 net revenue $116.9M, net loss $29.5M, Adj EBITDA $26.3M
Net revenue of $116.9M, down 3% sequentially from Q4 2025; retail $83.1M, wholesale $33.8M.
Ascend Wellness Holdings completes Class B conversion and annual meeting
On May 4, 2026, all 65,000 outstanding Class B shares of Ascend Wellness automatically converted into Class A shares.
Ascend Wellness reports Q4 2025 revenue $120.5M; net loss widens to $48.7M; FY revenue $500.6M
Q4 2025 revenue $120.5M (down 3.4% sequentially); FY2025 revenue $500.6M (down 10.9% YoY).
Ascend Wellness settles arbitration with GTI for $17M, down from $19.7M award
Settlement payment of $17M made to GTI, resolving $19.7M arbitration award from Feb 6.
Ascend Wellness prelim Q4 rev ~$120M, FY rev ~$500M; GTI arbitration award
Q4 2025 net revenue ~$120M, Adjusted EBITDA ~$30M (25% margin); FY 2025 net revenue ~$500M, Adj EBITDA ~$117M (23% margin).
Ascend Wellness loses arbitration to Green Thumb; net award $19.7M
Arbitrator found both Ascend and Green Thumb breached purchase-obligation agreement from June 2018.
Ascend Wellness Q3 2025: net loss $25.8M, adj EBITDA $31.1M (24.9% margin), revenue $124.7M
Net revenue $124.7M, down 2% sequentially; retail $83.8M (-3.1%), wholesale $41.0M (+0.3%).
Ascend Wellness Q2 revenue $127.3M flat; net loss widens to $24.4M
Net revenue $127.3M, flat QoQ (down 0.5%); retail revenue up 2.5% to $86.5M, wholesale down 6.4%.
Ascend Wellness issues $50M 12.75% senior secured notes due 2029 to repay credit facility
Issued $50M aggregate principal of 12.75% senior secured notes due 2029 at 97.5% of face value.
Ascend Wellness Q1 2025 net revenue $128M, Adj EBITDA $27M, cash from ops positive $5.9M
Net revenue of $128.0M; Adjusted EBITDA of $27.0M (non-GAAP); Adjusted Gross Margin 40.8%.
All six board nominees (Kurtin, Perullo, Swid, Gold, Brill, Francis) elected; each received over 95 million votes for.
Ascend Wellness Holdings dismisses MGO and appoints Withum as new auditor
MGO dismissed as independent auditor effective March 19, 2025; no adverse opinions or modifications in its reports for 2023 and 2024.
Ascend Wellness Q4 2024 Adj. EBITDA $30.2M; FY revenue $562M (+8% YoY)
FY2024 net revenue $562M (+8% YoY); Adj. EBITDA $116M (+9% YoY).
Ascend Wellness issues $15M additional 12.75% senior secured notes due 2029 at 97% of face
Issued $15M of 12.75% senior secured notes due 2029 at 97% face value, plus accrued interest from July 16, 2024.
Ascend Wellness authorizes share buyback of up to 5% of shares or $2.25M
Board approved NCIB effective Jan 2, 2025 to repurchase up to 10,215,690 shares (~5% of outstanding) or $2.25M, whichever is less.
Ascend Wellness repurchases 11M shares (over 5% outstanding) at discount from institutional investor
Repurchased 11,000,000 Class A common shares from an institutional investor in a private transaction, representing over 5% of outstanding shares.
Ascend Wellness Q3 net revenue $141.6M flat YoY; net loss widens to $28.3M, Adj EBITDA down 14.9%
Net revenue $141.6M (+0.3% YoY); retail $93.6M (-7.6% YoY), wholesale $48.0M (+20.1% YoY).
Ascend Wellness replaces CEO and CFO; appoints Samuel Brill as CEO, Roman Nemchenko as CFO
John Hartmann removed as CEO effective Aug 26, 2024; Samuel Brill (formerly Lead Independent Director) appointed CEO.
Ascend Wellness Q2 net revenue $141.5M (+15% YoY); net loss of $21.8M vs prior year net income
Net revenue $141.5M, up 15.1% YoY; gross wholesale revenue +30.1% YoY to $79.6M.
Ascend Wellness closes $235M 12.75% notes due 2029, refinances term loan
Issued $235M senior secured notes at 94.75% of face value, maturing July 16, 2029.
Ascend Wellness issues $235M 12.75% senior secured notes due 2029 to refinance term loan
Private placement of $235M 12.75% Senior Secured Notes due 2029, issued at 94.75% of face value.
Ascend Wellness appoints Julie Francis to board; expands to 7 directors
Julie Francis appointed to Board effective June 3, 2024; board expands from 6 to 7.
Ascend Wellness Q1 net revenue $142.4M (+25% YoY); Adj. EBITDA $32.5M (+39% YoY)
Gross revenue $174.2M (+23.4% YoY); net loss $18.2M vs $18.5M a year ago.
Ascend Wellness transitions Chairman Kurtin and EVP Perullo; separation payments total $5.78M
Abner Kurtin retains Executive Chairman role with $200k salary; $150k RSU; no bonus or severance.
Q4 net revenue $140M (+25% YoY), adjusted EBITDA $32M; first full year positive ops cash flow
Q4 2023 net revenue $140.2M, up 25.0% YoY; full year net revenue $518.6M, up 27.8% YoY.
the Board appointed Samuel Brill as Chief Executive Officer of the Company and removed him as Lead Independent Director of the Board
John Hartmann no longer serves as Chief Executive Officer of the Company.
the Board appointed Samuel Brill as Chief Executive Officer of the Company and removed him as Lead Independent Director of the Board, while maintaining his appointment as director of the Company, effective immediately.
On May 31, 2024, the board of directors (the “Board”) of Ascend Wellness Holdings, Inc. (the “Company”), upon recommendation of the Compensation and Corporate Governance Committee of the Board, appointed Julie Francis as a director of the Company, effective June 3, 2024
Max materiality 0.85 · Median 0.65 · Most common event earnings